 Richard Tobin
Concepts (207)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myeloid-Derived Suppressor Cells | 5 | 2024 | 56 | 2.260 |
Why?
| | Melanoma | 7 | 2024 | 619 | 1.500 |
Why?
| | Histocompatibility Antigens Class II | 5 | 2019 | 352 | 0.800 |
Why?
| | Hematologic Neoplasms | 1 | 2024 | 137 | 0.800 |
Why?
| | Neoplasms, Second Primary | 1 | 2023 | 92 | 0.780 |
Why?
| | Tretinoin | 2 | 2023 | 122 | 0.780 |
Why?
| | Antigens, Differentiation, B-Lymphocyte | 4 | 2017 | 33 | 0.740 |
Why?
| | Ipilimumab | 2 | 2019 | 27 | 0.660 |
Why?
| | Neoplasms | 3 | 2024 | 2097 | 0.620 |
Why?
| | Lymphocyte Activation | 4 | 2020 | 1037 | 0.590 |
Why?
| | Tumor Escape | 2 | 2017 | 35 | 0.590 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 152 | 0.540 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 1355 | 0.480 |
Why?
| | T-Lymphocyte Subsets | 4 | 2024 | 383 | 0.430 |
Why?
| | Neurodegenerative Diseases | 1 | 2014 | 92 | 0.430 |
Why?
| | Skin Neoplasms | 3 | 2024 | 756 | 0.400 |
Why?
| | CD8-Positive T-Lymphocytes | 3 | 2024 | 687 | 0.340 |
Why?
| | Brain Injuries | 1 | 2014 | 461 | 0.340 |
Why?
| | Pre-Eclampsia | 3 | 2017 | 165 | 0.320 |
Why?
| | Spleen | 4 | 2022 | 487 | 0.310 |
Why?
| | Brain Injuries, Traumatic | 2 | 2022 | 301 | 0.270 |
Why?
| | Genes, MHC Class II | 2 | 2017 | 69 | 0.260 |
Why?
| | T-Lymphocytes | 3 | 2017 | 1736 | 0.240 |
Why?
| | Dasatinib | 1 | 2024 | 46 | 0.230 |
Why?
| | Mucous Membrane | 1 | 2024 | 108 | 0.220 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2024 | 111 | 0.210 |
Why?
| | Brain | 1 | 2014 | 2371 | 0.210 |
Why?
| | Antineoplastic Agents | 3 | 2024 | 1879 | 0.210 |
Why?
| | Interleukin-4 | 2 | 2014 | 206 | 0.210 |
Why?
| | Lysophospholipids | 1 | 2023 | 65 | 0.210 |
Why?
| | Myocarditis | 1 | 2024 | 93 | 0.210 |
Why?
| | Vagotomy | 1 | 2022 | 34 | 0.210 |
Why?
| | Capillary Permeability | 2 | 2013 | 135 | 0.200 |
Why?
| | Lymphocytes | 2 | 2020 | 330 | 0.200 |
Why?
| | Tumor Microenvironment | 1 | 2024 | 430 | 0.180 |
Why?
| | Macrophage Migration-Inhibitory Factors | 1 | 2020 | 10 | 0.180 |
Why?
| | Killer Cells, Natural | 1 | 2023 | 380 | 0.180 |
Why?
| | B-Lymphocytes | 3 | 2020 | 766 | 0.180 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2024 | 615 | 0.170 |
Why?
| | Immunotherapy | 1 | 2024 | 474 | 0.170 |
Why?
| | Splenectomy | 1 | 2020 | 52 | 0.170 |
Why?
| | Cytokines | 3 | 2016 | 1840 | 0.170 |
Why?
| | Renal Circulation | 1 | 2019 | 53 | 0.170 |
Why?
| | Haploinsufficiency | 1 | 2019 | 42 | 0.160 |
Why?
| | CTLA-4 Antigen | 1 | 2019 | 76 | 0.160 |
Why?
| | Lipopolysaccharides | 2 | 2019 | 821 | 0.160 |
Why?
| | Animals | 16 | 2024 | 31694 | 0.160 |
Why?
| | Inflammation | 5 | 2016 | 2477 | 0.150 |
Why?
| | Humans | 19 | 2024 | 114623 | 0.150 |
Why?
| | Septins | 1 | 2018 | 40 | 0.150 |
Why?
| | Monocytes | 2 | 2020 | 502 | 0.150 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2021 | 213 | 0.140 |
Why?
| | Peritoneal Diseases | 1 | 2016 | 4 | 0.140 |
Why?
| | Granulocytes | 1 | 2017 | 77 | 0.140 |
Why?
| | Mice, Inbred C57BL | 6 | 2017 | 4689 | 0.140 |
Why?
| | Histamine | 1 | 2016 | 56 | 0.140 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2018 | 179 | 0.140 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2018 | 192 | 0.140 |
Why?
| | Fas Ligand Protein | 2 | 2015 | 57 | 0.140 |
Why?
| | Pancreatic Cyst | 1 | 2017 | 47 | 0.130 |
Why?
| | fas Receptor | 2 | 2015 | 91 | 0.130 |
Why?
| | Mast Cells | 1 | 2016 | 116 | 0.130 |
Why?
| | Homeostasis | 1 | 2019 | 573 | 0.130 |
Why?
| | Hepatic Encephalopathy | 1 | 2015 | 19 | 0.130 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2019 | 339 | 0.130 |
Why?
| | Microvessels | 2 | 2013 | 68 | 0.130 |
Why?
| | Caspase 3 | 2 | 2013 | 235 | 0.120 |
Why?
| | Endothelium, Vascular | 4 | 2014 | 843 | 0.120 |
Why?
| | Lyme Disease | 1 | 2015 | 32 | 0.120 |
Why?
| | Disease Models, Animal | 4 | 2022 | 3531 | 0.120 |
Why?
| | Signal Transduction | 5 | 2023 | 4509 | 0.120 |
Why?
| | Mice | 9 | 2024 | 14860 | 0.120 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2015 | 97 | 0.120 |
Why?
| | Neuroimmunomodulation | 1 | 2014 | 70 | 0.120 |
Why?
| | Toll-Like Receptors | 2 | 2017 | 167 | 0.120 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2015 | 194 | 0.110 |
Why?
| | Immunity, Innate | 2 | 2020 | 720 | 0.110 |
Why?
| | Adaptive Immunity | 1 | 2014 | 155 | 0.110 |
Why?
| | Staurosporine | 1 | 2013 | 21 | 0.110 |
Why?
| | Male | 11 | 2024 | 55554 | 0.110 |
Why?
| | NF-kappa B | 1 | 2016 | 638 | 0.100 |
Why?
| | bcl-X Protein | 1 | 2012 | 38 | 0.100 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2012 | 35 | 0.100 |
Why?
| | Blood Pressure | 2 | 2019 | 1538 | 0.100 |
Why?
| | Interleukin-10 | 1 | 2014 | 299 | 0.100 |
Why?
| | Fetal Blood | 1 | 2014 | 270 | 0.100 |
Why?
| | Immunologic Factors | 1 | 2014 | 220 | 0.100 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2018 | 1141 | 0.100 |
Why?
| | Dendritic Cells | 1 | 2015 | 435 | 0.100 |
Why?
| | Antihypertensive Agents | 1 | 2014 | 429 | 0.090 |
Why?
| | Shock, Hemorrhagic | 1 | 2013 | 199 | 0.090 |
Why?
| | Infant, Premature | 1 | 2014 | 476 | 0.090 |
Why?
| | Apoptosis | 3 | 2015 | 2362 | 0.090 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2024 | 22 | 0.080 |
Why?
| | Mice, Transgenic | 1 | 2014 | 1947 | 0.080 |
Why?
| | Aged | 4 | 2024 | 19061 | 0.080 |
Why?
| | Fetal Growth Retardation | 1 | 2014 | 467 | 0.080 |
Why?
| | Cell Line, Tumor | 3 | 2024 | 2710 | 0.080 |
Why?
| | Inflammation Mediators | 3 | 2016 | 477 | 0.070 |
Why?
| | Rats | 4 | 2019 | 4958 | 0.070 |
Why?
| | Middle Aged | 4 | 2024 | 26719 | 0.070 |
Why?
| | Female | 8 | 2024 | 59466 | 0.070 |
Why?
| | Cells, Cultured | 4 | 2017 | 3881 | 0.070 |
Why?
| | Adenocarcinoma | 1 | 2012 | 795 | 0.070 |
Why?
| | Adult | 4 | 2024 | 30528 | 0.070 |
Why?
| | Survival Analysis | 2 | 2020 | 1211 | 0.060 |
Why?
| | Flow Cytometry | 3 | 2014 | 1083 | 0.060 |
Why?
| | Azepines | 1 | 2024 | 75 | 0.060 |
Why?
| | Reactive Oxygen Species | 2 | 2019 | 531 | 0.060 |
Why?
| | Toll-Like Receptor 3 | 2 | 2014 | 26 | 0.060 |
Why?
| | Proteinuria | 2 | 2014 | 77 | 0.060 |
Why?
| | Monitoring, Immunologic | 1 | 2023 | 23 | 0.050 |
Why?
| | Receptors, Lysophosphatidic Acid | 1 | 2023 | 29 | 0.050 |
Why?
| | Triazoles | 1 | 2024 | 131 | 0.050 |
Why?
| | Immunoglobulins | 1 | 2023 | 142 | 0.050 |
Why?
| | Receptors, KIR | 1 | 2023 | 92 | 0.050 |
Why?
| | Interleukin-2 | 1 | 2024 | 413 | 0.050 |
Why?
| | Thymus Gland | 1 | 2023 | 296 | 0.050 |
Why?
| | Uveal Neoplasms | 1 | 2021 | 8 | 0.050 |
Why?
| | Vagus Nerve | 1 | 2022 | 79 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2023 | 309 | 0.050 |
Why?
| | Molecular Targeted Therapy | 1 | 2024 | 347 | 0.050 |
Why?
| | Rats, Sprague-Dawley | 2 | 2019 | 2218 | 0.050 |
Why?
| | Ligands | 1 | 2023 | 561 | 0.050 |
Why?
| | Gestational Age | 2 | 2014 | 759 | 0.050 |
Why?
| | Nerve Degeneration | 1 | 2020 | 40 | 0.050 |
Why?
| | Lung | 1 | 2013 | 3558 | 0.040 |
Why?
| | Receptors, CCR | 1 | 2020 | 7 | 0.040 |
Why?
| | Platelet Count | 1 | 2020 | 81 | 0.040 |
Why?
| | Basophils | 1 | 2020 | 64 | 0.040 |
Why?
| | Lymphocyte Subsets | 1 | 2020 | 79 | 0.040 |
Why?
| | Genomics | 1 | 2024 | 635 | 0.040 |
Why?
| | Nephrons | 1 | 2019 | 16 | 0.040 |
Why?
| | Cyclic N-Oxides | 1 | 2019 | 30 | 0.040 |
Why?
| | Spin Labels | 1 | 2019 | 44 | 0.040 |
Why?
| | Leukocyte Count | 1 | 2020 | 293 | 0.040 |
Why?
| | Pregnancy | 3 | 2017 | 5517 | 0.040 |
Why?
| | Postoperative Period | 1 | 2020 | 289 | 0.040 |
Why?
| | Astrocytes | 1 | 2020 | 162 | 0.040 |
Why?
| | Pancreaticoduodenectomy | 1 | 2020 | 133 | 0.040 |
Why?
| | Myeloid Cells | 1 | 2020 | 126 | 0.040 |
Why?
| | Immunotherapy, Adoptive | 1 | 2020 | 183 | 0.040 |
Why?
| | Mutation | 2 | 2019 | 3344 | 0.040 |
Why?
| | Vasoconstriction | 1 | 2019 | 177 | 0.040 |
Why?
| | Placenta | 2 | 2014 | 625 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2024 | 1518 | 0.040 |
Why?
| | Neoplasm Invasiveness | 1 | 2018 | 442 | 0.040 |
Why?
| | Disease Progression | 1 | 2024 | 2380 | 0.040 |
Why?
| | Cromolyn Sodium | 1 | 2016 | 13 | 0.030 |
Why?
| | Toll-Like Receptor 4 | 1 | 2019 | 287 | 0.030 |
Why?
| | Mesentery | 1 | 2016 | 53 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2019 | 367 | 0.030 |
Why?
| | Rats, Inbred F344 | 1 | 2016 | 241 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2018 | 385 | 0.030 |
Why?
| | Cell Count | 1 | 2017 | 303 | 0.030 |
Why?
| | Lymphatic Vessels | 1 | 2016 | 54 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2018 | 698 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2017 | 274 | 0.030 |
Why?
| | Autoimmune Diseases | 1 | 2019 | 382 | 0.030 |
Why?
| | Pentacyclic Triterpenes | 1 | 2015 | 13 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2024 | 12542 | 0.030 |
Why?
| | Triterpenes | 1 | 2015 | 17 | 0.030 |
Why?
| | Borrelia burgdorferi | 1 | 2015 | 12 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 2015 | 271 | 0.030 |
Why?
| | Antigens, Bacterial | 1 | 2015 | 112 | 0.030 |
Why?
| | Poly I-C | 1 | 2014 | 51 | 0.030 |
Why?
| | Interleukin-17 | 1 | 2015 | 104 | 0.030 |
Why?
| | Fetal Death | 1 | 2014 | 50 | 0.030 |
Why?
| | Toll-Like Receptor 2 | 1 | 2015 | 110 | 0.030 |
Why?
| | Mice, Inbred Strains | 1 | 2015 | 396 | 0.030 |
Why?
| | Lipoproteins | 1 | 2015 | 159 | 0.030 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2014 | 66 | 0.030 |
Why?
| | HLA-DR Antigens | 1 | 2015 | 219 | 0.030 |
Why?
| | CD3 Complex | 1 | 2014 | 92 | 0.030 |
Why?
| | Antigen Presentation | 1 | 2015 | 188 | 0.030 |
Why?
| | Caspases | 1 | 2015 | 245 | 0.030 |
Why?
| | CD4 Antigens | 1 | 2014 | 123 | 0.030 |
Why?
| | Necrosis | 1 | 2014 | 211 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2020 | 2186 | 0.030 |
Why?
| | Forkhead Transcription Factors | 1 | 2014 | 170 | 0.030 |
Why?
| | Adherens Junctions | 1 | 2013 | 26 | 0.030 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2013 | 64 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2018 | 785 | 0.030 |
Why?
| | Caspase Inhibitors | 1 | 2013 | 78 | 0.030 |
Why?
| | Immunoprecipitation | 1 | 2012 | 151 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2014 | 951 | 0.020 |
Why?
| | Cell Communication | 1 | 2013 | 279 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2013 | 396 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2014 | 1230 | 0.020 |
Why?
| | Birth Weight | 1 | 2014 | 440 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2013 | 785 | 0.020 |
Why?
| | Colonic Neoplasms | 1 | 2012 | 215 | 0.020 |
Why?
| | Down-Regulation | 1 | 2012 | 594 | 0.020 |
Why?
| | Blotting, Western | 1 | 2012 | 1147 | 0.020 |
Why?
| | Adoptive Transfer | 1 | 2010 | 195 | 0.020 |
Why?
| | Biomarkers | 1 | 2020 | 3408 | 0.020 |
Why?
| | Cell Separation | 1 | 2010 | 291 | 0.020 |
Why?
| | Chronic Disease | 1 | 2015 | 1578 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2020 | 6344 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2012 | 1629 | 0.020 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2012 | 636 | 0.020 |
Why?
| | Mitochondria | 1 | 2013 | 747 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2013 | 2565 | 0.020 |
Why?
| | Hypertension | 1 | 2013 | 1056 | 0.020 |
Why?
| | Time Factors | 1 | 2014 | 6112 | 0.010 |
Why?
| | Prospective Studies | 1 | 2014 | 6217 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2012 | 2177 | 0.010 |
Why?
|
|
Tobin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|